A long-term, open-label, flexible-dose, extension study evaluating the safety and tolerability of Lu AA21004 (15 and 20 mg/day) in patients with Major Depressive Disorder [EXTENSION OF 700054730]
Latest Information Update: 28 Apr 2023
At a glance
- Drugs Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Lundbeck A/S
- 01 Apr 2023 Results of pooled analysis from NCT00761306 and NCT01323478 assessing safety and efficacy of vortioxetine in the management of major depressive disorder published in the Current Medical Research and Opinion
- 01 Sep 2015 Pooled analysis results (NCT00761306, NCT00694304, NCT00707980, NCT01323478 and NCT01152996) presented at the 28th Annual Congress of the European College of Neuropsychopharmacology.
- 01 Sep 2015 Pooled subgroup analysis results ((NCT00761306, NCT00694304, NCT00707980, NCT01323478 and NCT01152996)) presented at the 28th Annual Congress of the European College of Neuropsychopharmacology.